Vanda Pharmaceuticals (VNDA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 46/100 (MEDIUM), 15.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.55% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- Generalized — VNDA PDUFA 2026-12-12
Recent News & SEC Filings
- Vanda puts anxiety drug’s development on ice after Phase III fail
- Vanda Pharmaceuticals stock falls after anxiety drug trial fails
- Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
- Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
- VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
- Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
- Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
- Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Vanda Pharmaceuticals.
Full VNDA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.